Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Labianca

Showing results (111-120 of 174) with videos related to

Pageof 18
Sort By:
Journal of Geriatric Oncology|July 30, 2016
Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT databaseDemetris Papamichael, Lindsay A Renfro, Christiana Matthaiou, et al.
British Journal of Cancer|September 20, 2017
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trialRiccardo Giampieri, Marco Puzzoni, Bruno Daniele, et al.
Cancer Treatment Reviews|June 15, 2021
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysisRichard Adams, Kaitlyn Goey, Benoist Chibaudel, et al.
Clinical Lung Cancer|May 10, 2011
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutationsGabriella Farina, Flavia Longo, Olga Martelli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 12, 2014
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC)Rodolfo Passalacqua, Caterina Caminiti, Sebastiano Buti, et al.
Oncotarget|September 24, 2015
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenibLuca Faloppi, Maristella Bianconi, Riccardo Giampieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trialsEmmanuel Mitry, Anthony L A Fields, Harry Bleiberg, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 6, 2013
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II studyStefano Cascinu, Rossana Berardi, Alberto Sobrero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2004
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?Sharlene Gill, Charles L Loprinzi, Daniel J Sargent, et al.
The Lancet. Oncology|July 26, 2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialMarina Chiara Garassino, Olga Martelli, Massimo Broggini, et al.
Pageof 18

Showing results (111-120 of 174) with videos related to

Sort By:
Pageof 18
Journal of Geriatric Oncology|July 30, 2016
Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT databaseDemetris Papamichael, Lindsay A Renfro, Christiana Matthaiou, et al.
British Journal of Cancer|September 20, 2017
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trialRiccardo Giampieri, Marco Puzzoni, Bruno Daniele, et al.
Cancer Treatment Reviews|June 15, 2021
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysisRichard Adams, Kaitlyn Goey, Benoist Chibaudel, et al.
Clinical Lung Cancer|May 10, 2011
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutationsGabriella Farina, Flavia Longo, Olga Martelli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 12, 2014
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC)Rodolfo Passalacqua, Caterina Caminiti, Sebastiano Buti, et al.
Oncotarget|September 24, 2015
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenibLuca Faloppi, Maristella Bianconi, Riccardo Giampieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trialsEmmanuel Mitry, Anthony L A Fields, Harry Bleiberg, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 6, 2013
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II studyStefano Cascinu, Rossana Berardi, Alberto Sobrero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2004
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?Sharlene Gill, Charles L Loprinzi, Daniel J Sargent, et al.
The Lancet. Oncology|July 26, 2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialMarina Chiara Garassino, Olga Martelli, Massimo Broggini, et al.
Pageof 18